Absci (ABSI) vs iSpecimen (ISPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci is the larger company by market cap ($1.58 billion vs $2.8 million), about 571.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ABSI | ISPC |
|---|---|---|
| Share price | $9.22 | $1.10 |
| Market cap | $1.58B | $2.77M |
| 1-day change | -10.22% | +2.80% |
| YTD return | +164.18% | — |
| 1-year return | +146.52% | — |
| 5-year return | -13.26% | — |
| EPS (TTM) | $-0.71 | $-53.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $40.04 |
| 52-week low | $2.24 | $1.02 |
| Distance from 52-week high | -23.52% | -97.25% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +56.18% | — |
| Average volume | 3.42M | 681.17K |
| Shares outstanding | 171.61M | 2.52M |
| Employees | 140 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Absci is about 571.1 times larger than iSpecimen by market value ($1.58B vs $2.77M).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
ABSI vs ISPC FAQ
Which is bigger, Absci or iSpecimen?
Absci (ABSI) is larger, with a market capitalization of $1.58B compared with $2.77M for iSpecimen (ISPC).
Are Absci and iSpecimen in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.